ReviewOncology2011
Combination therapy for renal cell cancer: what are possible options?
Review in Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma.International journal of oncology · 2019Article
- βArrestin2 Mediates Renal Cell Carcinoma Tumor Growth.Scientific reports · 2018Article
- Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells.Journal of kidney cancer and VHL · 2018Article
- Prostaglandin E2 receptor 4 mediates renal cell carcinoma intravasation and metastasis.Cancer letters · 2017Article
- Specific immunotherapy in renal cancer: a systematic review.Therapeutic advances in urology · 2017Review
- Diverse array-designed modes of combination therapies in Fangjiomics.Acta pharmacologica Sinica · 2015Review
- Sunitinib resistance in renal cell carcinoma.Journal of kidney cancer and VHL · 2014Article
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).Cancer chemotherapy and pharmacology · 2014Article
- Tivozanib in the treatment of renal cell carcinoma.Biologics : targets & therapy · 2013Article
- Overview of cancer vaccines: considerations for development.Human vaccines & immunotherapeutics · 2012Review
- Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.Langenbeck's archives of surgery · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
Antiangiogenic therapy has shown promise in the treatment of patients with renal cell carcinoma (RCC). Two classes of antiangiogenic drugs, the anti-vascular endothelial growth factor antibody bevacizumab and the tyrosine kinase inhibitors sorafenib, sunitinib and pazopanib, have shown efficacy in patients with RCC and are approved by the US Food and Drug Administration for treatment of this cancer. In practice, the clinical benefit of antiangiogenic drugs in RCC has been heterogeneous, and in patients who do respond, benefits are modest and/or short-lived. To improve efficacy, combination targeted therapy has been attempted, but with either very limited additional efficacy or nontolerable toxicities. Recent advances in the molecular understanding of tumor angiogenesis and mechanism of resistance, along with the rapid development of targeted drug discovery, have made it possible to further explore novel combination therapy for RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.